… More alemtuzumab relapsing–remitting multiple sclerosis patients are free of clinical disease
activity at five years (Poster PD6003). Presented at the American Academy of Neurology, …

… clinical diagnosis and prognostication of multiple sclerosis patients. Future research will enable
… , which will enable timely personalized treatment in individual multiple sclerosis patients. …

… in people with multiple sclerosis. … on multiple sclerosis patients’ activities of daily living.
There is limited understanding of the level of fatigue experienced by people with multiple sclerosis…

… In striking contrast with the general trend, 47.5% of deaths in Welsh patients … multiple
sclerosis (MS) among studies Table 4 Main causes of death among patients with multiple sclerosis …

… contribute to progressive multiple sclerosis (MS). (1) Classic inflammatory white matter
plaques are typically associated with relapses but also occur in patients who progress gradually …

This review describes the many neuropsychiatric abnormalities associated with multiple
sclerosis (MS). These may be broadly divided into 2 categories: disorders of mood, affect, and …

… Patients with primary progressive multiple sclerosis have fewer gadolinium-enhanced …
patients with secondary progressive multiple sclerosis. Progressive relapsing multiple sclerosis is …

The aim of this study was to investigate the prevalence of symptoms of depression and
anxiety amongst multiple sclerosis (MS) patients, and the associations with demographic and …

… to describe the quality of life in patients with multiple sclerosis (MS) given immunological …
nine patients given immunological treatment were matched with the same number of patients …

… do not exist in MS patients according to current data (see below). However, we recently
observed that clonally expanded T cells from the CSF of MS patients are capable of utilizing all …